Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:INDP NASDAQ:LRMR NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.60$0.78$0.54▼$9.76$84.07M1.751.33 million shs1.01 million shsINDPIndaptus Therapeutics$3.03$2.59$0.92▼$13.40$343.12M1.11756,862 shs146,750 shsLRMRLarimar Therapeutics$3.26$3.64$2.71▼$6.42$338.66M0.833.00 million shs2.44 million shsQNCXQuince Therapeutics$17.23$21.52$15.10▼$909.98$16.85M1.427,208 shs45,013 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma0.00%+9.31%-16.26%-47.26%-92.37%INDPIndaptus Therapeutics0.00%-10.41%-36.21%+89.38%-72.92%LRMRLarimar Therapeutics0.00%-10.93%-0.91%-31.94%+4.82%QNCXQuince Therapeutics0.00%-8.69%-21.68%-12.98%-94.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.60$0.78$0.54▼$9.76$84.07M1.751.33 million shs1.01 million shsINDPIndaptus Therapeutics$3.03$2.59$0.92▼$13.40$343.12M1.11756,862 shs146,750 shsLRMRLarimar Therapeutics$3.26$3.64$2.71▼$6.42$338.66M0.833.00 million shs2.44 million shsQNCXQuince Therapeutics$17.23$21.52$15.10▼$909.98$16.85M1.427,208 shs45,013 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma0.00%+9.31%-16.26%-47.26%-92.37%INDPIndaptus Therapeutics0.00%-10.41%-36.21%+89.38%-72.92%LRMRLarimar Therapeutics0.00%-10.93%-0.91%-31.94%+4.82%QNCXQuince Therapeutics0.00%-8.69%-21.68%-12.98%-94.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/AINDPIndaptus Therapeutics 1.00SellN/AN/ALRMRLarimar Therapeutics 3.09Buy$12.71290.01% UpsideQNCXQuince Therapeutics 2.20Hold$690.003,904.64% UpsideCurrent Analyst Ratings BreakdownLatest AIFC, LRMR, INDP, and QNCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026LRMRLarimar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.006/30/2026LRMRLarimar Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026LRMRLarimar Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $5.006/29/2026QNCXQuince Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026QNCXQuince Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/24/2026QNCXQuince Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.006/23/2026QNCXQuince Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$80.006/23/2026QNCXQuince Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$80.005/27/2026LRMRLarimar Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/18/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $12.005/1/2026QNCXQuince Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M3.38N/AN/A$9.07 per share0.07INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$0.94 per shareN/AQNCXQuince TherapeuticsN/AN/AN/AN/A($128.18) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-2,483.94%-68.25%-62.43%N/AINDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)LRMRLarimar Therapeutics-$165.67M-$2.06N/AN/AN/AN/A-134.14%-96.00%8/13/2026 (Estimated)QNCXQuince Therapeutics-$83.98M-$212.40N/AN/AN/AN/AN/A-67.99%8/11/2026 (Estimated)Latest AIFC, LRMR, INDP, and QNCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026AIFCALT5 SigmaN/A-$2.14N/A-$2.14N/A$4.71 million5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/14/2026Q1 2026LRMRLarimar Therapeutics-$0.53-$0.31+$0.22-$0.31N/AN/A5/11/2026Q1 2026QNCXQuince Therapeutics-$26.00-$0.59+$25.41$57.60N/AN/A4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.030.820.82INDPIndaptus TherapeuticsN/A2.342.34LRMRLarimar TherapeuticsN/A4.294.29QNCXQuince TherapeuticsN/A2.922.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%INDPIndaptus Therapeutics7.06%LRMRLarimar Therapeutics91.92%QNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%INDPIndaptus Therapeutics23.60%LRMRLarimar Therapeutics4.50%QNCXQuince Therapeutics7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170139.84 million139.54 millionN/AINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableLRMRLarimar Therapeutics30103.88 million99.21 millionOptionableQNCXQuince Therapeutics60980,000909,000OptionableAIFC, LRMR, INDP, and QNCX HeadlinesRecent News About These CompaniesQuince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | BenzingaJuly 2 at 8:01 AM | benzinga.comQuince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory BoardJune 30, 2026 | globenewswire.comQuince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks TranscriptJune 11, 2026 | seekingalpha.comQuince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled TherapyJune 2, 2026 | insidermonkey.comQuince Therapeutics Regains Nasdaq Compliance, Avoids Delisting RiskMay 24, 2026 | theglobeandmail.comQuince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks TranscriptMay 18, 2026 | seekingalpha.comUPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDMay 18, 2026 | globenewswire.comQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDMay 18, 2026 | globenewswire.comQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary PipelineMay 18, 2026 | globenewswire.comQuince Therapeutics (QNCX) price target increased by 100.00% to 81.60May 15, 2026 | msn.comQuince Therapeutics (QNCX) price target increased by 900.00% to 40.80April 28, 2026 | msn.comQuince Therapeutics Delays Annual 10-K FilingApril 27, 2026 | theglobeandmail.comQuince Therapeutics settles $16.4M debt with $5.5M paymentMarch 30, 2026 | msn.comWhy did QNCX stock surge 40% in pre-market today?March 30, 2026 | msn.comQuince Therapeutics Settles Approximately $16.4 Million of DebtMarch 30, 2026 | businesswire.comBankruptcy threat looms as Quince runs out of optionsFebruary 13, 2026 | pharmaphorum.comPQuince Therapeutics stock plummets after revealing strategic alternativesFebruary 13, 2026 | au.investing.comQuince Therapeutics (QNCX) Stock Erupts 300% as Buyout Rumors EmergeFebruary 11, 2026 | blockonomi.comQuince Therapeutics stock soars after engaging LifeSci Capital as advisorFebruary 10, 2026 | au.investing.comWhy is QNCX stock up 60% pre-market after a near-total wipeout?February 10, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIFC, LRMR, INDP, and QNCX Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.60 0.00 (0.00%) As of 07/2/2026 04:00 PM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Indaptus Therapeutics NASDAQ:INDP$3.03 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.03 0.00 (0.00%) As of 07/2/2026 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Larimar Therapeutics NASDAQ:LRMR$3.26 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.29 +0.03 (+0.80%) As of 07/2/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Quince Therapeutics NASDAQ:QNCX$17.23 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$16.43 -0.80 (-4.64%) As of 07/2/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
